Provectus Pharmaceuticals Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc.

PVCT 0.0640

0.0%

Nov 7 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

Recommended by:

Mark Buczynski

To: Mark Buczynski who wrote (12730)	3/20/2014 8:16:49 PM
From: Jack Russell	1 Recommendation Read Replies (2) of 13111

Shows their intent is aggressive "acquire"... German drug giant Boehringer Ingelheim opens venture capital office in Cambridge From 12/6/13 Boston Business Journal... ... ultimate goal is to find promising companies that could be acquired by BI, and says “we would like to go beyond what our parent company is already doing.” That means Heidecker will be looking at companies working on drugs in fields like dermatology, opthamology and regenerative medicine, as well as therapeutic vaccines aimed at cancers. He said he’s focused on “neglected areas” of disease, rather than large, competitive fields like chronic obstructive pulmonary disease bizjournals.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next